Eintrag weiter verarbeiten
Online-Ressource

The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post...

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: Blood
Personen und Körperschaften: Verstovsek, Srdan, Kantarjian, Hagop M., Pardanani, Animesh D., Thomas, Deborah, Cortes, Jorge, Mesa, Ruben A., Hogan, William J., Redman, John R., Erickson-Viitanen, Sue, Levy, Richard, Vaddi, Kris, Bradley, Edward, Fridman, Jordan, Tefferi, Ayalew
In: Blood, 112, 2008, 11, S. 1762-1762
Format: E-Article
Sprache: Englisch
veröffentlicht:
American Society of Hematology
Schlagwörter:
Cell Biology
Hematology
Immunology
Biochemistry
author_facet Verstovsek, Srdan
Kantarjian, Hagop M.
Pardanani, Animesh D.
Thomas, Deborah
Cortes, Jorge
Mesa, Ruben A.
Hogan, William J.
Redman, John R.
Erickson-Viitanen, Sue
Levy, Richard
Vaddi, Kris
Bradley, Edward
Fridman, Jordan
Tefferi, Ayalew
Verstovsek, Srdan
Kantarjian, Hagop M.
Pardanani, Animesh D.
Thomas, Deborah
Cortes, Jorge
Mesa, Ruben A.
Hogan, William J.
Redman, John R.
Erickson-Viitanen, Sue
Levy, Richard
Vaddi, Kris
Bradley, Edward
Fridman, Jordan
Tefferi, Ayalew
author Verstovsek, Srdan
Kantarjian, Hagop M.
Pardanani, Animesh D.
Thomas, Deborah
Cortes, Jorge
Mesa, Ruben A.
Hogan, William J.
Redman, John R.
Erickson-Viitanen, Sue
Levy, Richard
Vaddi, Kris
Bradley, Edward
Fridman, Jordan
Tefferi, Ayalew
spellingShingle Verstovsek, Srdan
Kantarjian, Hagop M.
Pardanani, Animesh D.
Thomas, Deborah
Cortes, Jorge
Mesa, Ruben A.
Hogan, William J.
Redman, John R.
Erickson-Viitanen, Sue
Levy, Richard
Vaddi, Kris
Bradley, Edward
Fridman, Jordan
Tefferi, Ayalew
Blood
The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
Cell Biology
Hematology
Immunology
Biochemistry
author_sort verstovsek, srdan
spelling Verstovsek, Srdan Kantarjian, Hagop M. Pardanani, Animesh D. Thomas, Deborah Cortes, Jorge Mesa, Ruben A. Hogan, William J. Redman, John R. Erickson-Viitanen, Sue Levy, Richard Vaddi, Kris Bradley, Edward Fridman, Jordan Tefferi, Ayalew 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v112.11.1762.1762 <jats:title>Abstract</jats:title> <jats:p>Background : Myelofibrosis (MF) is characterized by progressive bone marrow dysfunction, extramedullary hematopoiesis, massive splenomegaly, elevated levels of inflammatory cytokines, severe constitutional symptoms, cachexia and premature death. INCB018424 is a potent, selective inhibitor of JAK 1 and 2 which has demonstrated impressive clinical activity in the early portion of a phase 1/2 study in patients with PMF and Post-PV/ET MF.</jats:p> <jats:p>Methods : Following the initial dose escalation phase with a BID schedule (N=11), both twice daily (10 mg BID to 25 mg BID, N=56) and once daily (25 mg QD to 200 mg QD, N= 37) dose regimens were explored. Endpoints included spleen size assessed by manual palpation, constitutional symptoms assessed using the Modified Myelofibrosis Symptom Assessment Form (MFSAF) and JAK2 allele burden. Exercise capacity is being assessed using the Six Minute Walk Test (6MWT), and body mass and composition are being assessed using standard methods. Safety was assessed by collection of adverse events and monitoring of laboratory data.</jats:p> <jats:p>Results : Over 100 patients are currently enrolled in the study, with a mean exposure to drug of &amp;gt; 5 months. Twenty percent of patients have received INCB018424 for &amp;gt; 9 months. INCB018424 is associated with a rapid reduction of splenomegaly in over 93% of patients from a mean baseline spleen size &amp;gt;20 cm, with 50% or greater reduction being observed in 35% of patients dosed with 10 mg BID or 50 mg QD, and 59% of patients dosed with 25mg BID regimens. These declines nearly always occur within the first month of therapy, with further, slower decreases often observed thereafter. In responding patients, spleen size reduction persists for the duration of therapy (currently up to one year follow-up). Constitutional symptoms are reported with high frequency in the study population as assessed by the MFSAF: night sweats, pruritis and fatigue were reported by &amp;gt;60%, &amp;gt;45% and &amp;gt;90% of patients respectively. Improvements in self-assessed symptom scores (mean % improvement of 40% to 60%) occurred by the first assessment at week 2. Activity limitations are also reported by a high proportion of MF patients; 70% of respondents reported impaired ability to exercise or get around, with a mean score &amp;gt;5 on the 11-point MFSAF scale; INCB018424 therapy was associated with rapid (within 2 weeks) and marked (40% or more) improvement in self-assessed score. There was a dose-dependent weight gain, most pronounced in patients with the lowest body mass index (BMI) values at baseline. Profound reductions in inflammatory cytokines were observed by the first evaluation at week 2 in virtually all patients, and were maintained during therapy. INCB018424 is generally well tolerated with the primary toxicity being dose-dependent grade 3 or 4 reversible thrombocytopenia which occurred in 0%, 18% and 32% of patients dosed with 10 mg BID, 50 mg QD or 25 mg BID.</jats:p> <jats:p>Conclusions : INCB18424 shows unprecedented and durable clinical efficacy in reducing spleen size and improving constitutional symptoms in patients with MF. Results from proactive dose modification regimens, assessments of exercise capacity, MRI-based spleen volume assessment and body composition determination will be presented.</jats:p> The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF). Blood
doi_str_mv 10.1182/blood.v112.11.1762.1762
facet_avail Online
Free
finc_class_facet Medizin
Chemie und Pharmazie
Biologie
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEyLjExLjE3NjIuMTc2Mg
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEyLjExLjE3NjIuMTc2Mg
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
imprint American Society of Hematology, 2008
imprint_str_mv American Society of Hematology, 2008
issn 0006-4971
1528-0020
issn_str_mv 0006-4971
1528-0020
language English
mega_collection American Society of Hematology (CrossRef)
match_str verstovsek2008thejakinhibitorincb018424demonstratesdurableandmarkedclinicalresponsesinprimarymyelofibrosispmfandpostpolycythemiaessentialthrombocythemiamyelofibrosispostpvetmf
publishDateSort 2008
publisher American Society of Hematology
recordtype ai
record_format ai
series Blood
source_id 49
title The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
title_unstemmed The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
title_full The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
title_fullStr The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
title_full_unstemmed The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
title_short The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
title_sort the jak inhibitor, incb018424, demonstrates durable and marked clinical responses in primary myelofibrosis (pmf) and post-polycythemia/essential thrombocythemia myelofibrosis (post pv/etmf).
topic Cell Biology
Hematology
Immunology
Biochemistry
url http://dx.doi.org/10.1182/blood.v112.11.1762.1762
publishDate 2008
physical 1762-1762
description <jats:title>Abstract</jats:title> <jats:p>Background : Myelofibrosis (MF) is characterized by progressive bone marrow dysfunction, extramedullary hematopoiesis, massive splenomegaly, elevated levels of inflammatory cytokines, severe constitutional symptoms, cachexia and premature death. INCB018424 is a potent, selective inhibitor of JAK 1 and 2 which has demonstrated impressive clinical activity in the early portion of a phase 1/2 study in patients with PMF and Post-PV/ET MF.</jats:p> <jats:p>Methods : Following the initial dose escalation phase with a BID schedule (N=11), both twice daily (10 mg BID to 25 mg BID, N=56) and once daily (25 mg QD to 200 mg QD, N= 37) dose regimens were explored. Endpoints included spleen size assessed by manual palpation, constitutional symptoms assessed using the Modified Myelofibrosis Symptom Assessment Form (MFSAF) and JAK2 allele burden. Exercise capacity is being assessed using the Six Minute Walk Test (6MWT), and body mass and composition are being assessed using standard methods. Safety was assessed by collection of adverse events and monitoring of laboratory data.</jats:p> <jats:p>Results : Over 100 patients are currently enrolled in the study, with a mean exposure to drug of &amp;gt; 5 months. Twenty percent of patients have received INCB018424 for &amp;gt; 9 months. INCB018424 is associated with a rapid reduction of splenomegaly in over 93% of patients from a mean baseline spleen size &amp;gt;20 cm, with 50% or greater reduction being observed in 35% of patients dosed with 10 mg BID or 50 mg QD, and 59% of patients dosed with 25mg BID regimens. These declines nearly always occur within the first month of therapy, with further, slower decreases often observed thereafter. In responding patients, spleen size reduction persists for the duration of therapy (currently up to one year follow-up). Constitutional symptoms are reported with high frequency in the study population as assessed by the MFSAF: night sweats, pruritis and fatigue were reported by &amp;gt;60%, &amp;gt;45% and &amp;gt;90% of patients respectively. Improvements in self-assessed symptom scores (mean % improvement of 40% to 60%) occurred by the first assessment at week 2. Activity limitations are also reported by a high proportion of MF patients; 70% of respondents reported impaired ability to exercise or get around, with a mean score &amp;gt;5 on the 11-point MFSAF scale; INCB018424 therapy was associated with rapid (within 2 weeks) and marked (40% or more) improvement in self-assessed score. There was a dose-dependent weight gain, most pronounced in patients with the lowest body mass index (BMI) values at baseline. Profound reductions in inflammatory cytokines were observed by the first evaluation at week 2 in virtually all patients, and were maintained during therapy. INCB018424 is generally well tolerated with the primary toxicity being dose-dependent grade 3 or 4 reversible thrombocytopenia which occurred in 0%, 18% and 32% of patients dosed with 10 mg BID, 50 mg QD or 25 mg BID.</jats:p> <jats:p>Conclusions : INCB18424 shows unprecedented and durable clinical efficacy in reducing spleen size and improving constitutional symptoms in patients with MF. Results from proactive dose modification regimens, assessments of exercise capacity, MRI-based spleen volume assessment and body composition determination will be presented.</jats:p>
container_issue 11
container_start_page 1762
container_title Blood
container_volume 112
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792339443032522756
geogr_code not assigned
last_indexed 2024-03-01T15:48:12.254Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=The+JAK+Inhibitor%2C+INCB018424%2C+Demonstrates+Durable+and+Marked+Clinical+Responses+in+Primary+Myelofibrosis+%28PMF%29+and+Post-Polycythemia%2FEssential+Thrombocythemia+Myelofibrosis+%28Post+PV%2FETMF%29.&rft.date=2008-11-16&genre=article&issn=1528-0020&volume=112&issue=11&spage=1762&epage=1762&pages=1762-1762&jtitle=Blood&atitle=The+JAK+Inhibitor%2C+INCB018424%2C+Demonstrates+Durable+and+Marked+Clinical+Responses+in+Primary+Myelofibrosis+%28PMF%29+and+Post-Polycythemia%2FEssential+Thrombocythemia+Myelofibrosis+%28Post+PV%2FETMF%29.&aulast=Tefferi&aufirst=Ayalew&rft_id=info%3Adoi%2F10.1182%2Fblood.v112.11.1762.1762&rft.language%5B0%5D=eng
SOLR
_version_ 1792339443032522756
author Verstovsek, Srdan, Kantarjian, Hagop M., Pardanani, Animesh D., Thomas, Deborah, Cortes, Jorge, Mesa, Ruben A., Hogan, William J., Redman, John R., Erickson-Viitanen, Sue, Levy, Richard, Vaddi, Kris, Bradley, Edward, Fridman, Jordan, Tefferi, Ayalew
author_facet Verstovsek, Srdan, Kantarjian, Hagop M., Pardanani, Animesh D., Thomas, Deborah, Cortes, Jorge, Mesa, Ruben A., Hogan, William J., Redman, John R., Erickson-Viitanen, Sue, Levy, Richard, Vaddi, Kris, Bradley, Edward, Fridman, Jordan, Tefferi, Ayalew, Verstovsek, Srdan, Kantarjian, Hagop M., Pardanani, Animesh D., Thomas, Deborah, Cortes, Jorge, Mesa, Ruben A., Hogan, William J., Redman, John R., Erickson-Viitanen, Sue, Levy, Richard, Vaddi, Kris, Bradley, Edward, Fridman, Jordan, Tefferi, Ayalew
author_sort verstovsek, srdan
container_issue 11
container_start_page 1762
container_title Blood
container_volume 112
description <jats:title>Abstract</jats:title> <jats:p>Background : Myelofibrosis (MF) is characterized by progressive bone marrow dysfunction, extramedullary hematopoiesis, massive splenomegaly, elevated levels of inflammatory cytokines, severe constitutional symptoms, cachexia and premature death. INCB018424 is a potent, selective inhibitor of JAK 1 and 2 which has demonstrated impressive clinical activity in the early portion of a phase 1/2 study in patients with PMF and Post-PV/ET MF.</jats:p> <jats:p>Methods : Following the initial dose escalation phase with a BID schedule (N=11), both twice daily (10 mg BID to 25 mg BID, N=56) and once daily (25 mg QD to 200 mg QD, N= 37) dose regimens were explored. Endpoints included spleen size assessed by manual palpation, constitutional symptoms assessed using the Modified Myelofibrosis Symptom Assessment Form (MFSAF) and JAK2 allele burden. Exercise capacity is being assessed using the Six Minute Walk Test (6MWT), and body mass and composition are being assessed using standard methods. Safety was assessed by collection of adverse events and monitoring of laboratory data.</jats:p> <jats:p>Results : Over 100 patients are currently enrolled in the study, with a mean exposure to drug of &amp;gt; 5 months. Twenty percent of patients have received INCB018424 for &amp;gt; 9 months. INCB018424 is associated with a rapid reduction of splenomegaly in over 93% of patients from a mean baseline spleen size &amp;gt;20 cm, with 50% or greater reduction being observed in 35% of patients dosed with 10 mg BID or 50 mg QD, and 59% of patients dosed with 25mg BID regimens. These declines nearly always occur within the first month of therapy, with further, slower decreases often observed thereafter. In responding patients, spleen size reduction persists for the duration of therapy (currently up to one year follow-up). Constitutional symptoms are reported with high frequency in the study population as assessed by the MFSAF: night sweats, pruritis and fatigue were reported by &amp;gt;60%, &amp;gt;45% and &amp;gt;90% of patients respectively. Improvements in self-assessed symptom scores (mean % improvement of 40% to 60%) occurred by the first assessment at week 2. Activity limitations are also reported by a high proportion of MF patients; 70% of respondents reported impaired ability to exercise or get around, with a mean score &amp;gt;5 on the 11-point MFSAF scale; INCB018424 therapy was associated with rapid (within 2 weeks) and marked (40% or more) improvement in self-assessed score. There was a dose-dependent weight gain, most pronounced in patients with the lowest body mass index (BMI) values at baseline. Profound reductions in inflammatory cytokines were observed by the first evaluation at week 2 in virtually all patients, and were maintained during therapy. INCB018424 is generally well tolerated with the primary toxicity being dose-dependent grade 3 or 4 reversible thrombocytopenia which occurred in 0%, 18% and 32% of patients dosed with 10 mg BID, 50 mg QD or 25 mg BID.</jats:p> <jats:p>Conclusions : INCB18424 shows unprecedented and durable clinical efficacy in reducing spleen size and improving constitutional symptoms in patients with MF. Results from proactive dose modification regimens, assessments of exercise capacity, MRI-based spleen volume assessment and body composition determination will be presented.</jats:p>
doi_str_mv 10.1182/blood.v112.11.1762.1762
facet_avail Online, Free
finc_class_facet Medizin, Chemie und Pharmazie, Biologie
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTEyLjExLjE3NjIuMTc2Mg
imprint American Society of Hematology, 2008
imprint_str_mv American Society of Hematology, 2008
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn 0006-4971, 1528-0020
issn_str_mv 0006-4971, 1528-0020
language English
last_indexed 2024-03-01T15:48:12.254Z
match_str verstovsek2008thejakinhibitorincb018424demonstratesdurableandmarkedclinicalresponsesinprimarymyelofibrosispmfandpostpolycythemiaessentialthrombocythemiamyelofibrosispostpvetmf
mega_collection American Society of Hematology (CrossRef)
physical 1762-1762
publishDate 2008
publishDateSort 2008
publisher American Society of Hematology
record_format ai
recordtype ai
series Blood
source_id 49
spelling Verstovsek, Srdan Kantarjian, Hagop M. Pardanani, Animesh D. Thomas, Deborah Cortes, Jorge Mesa, Ruben A. Hogan, William J. Redman, John R. Erickson-Viitanen, Sue Levy, Richard Vaddi, Kris Bradley, Edward Fridman, Jordan Tefferi, Ayalew 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v112.11.1762.1762 <jats:title>Abstract</jats:title> <jats:p>Background : Myelofibrosis (MF) is characterized by progressive bone marrow dysfunction, extramedullary hematopoiesis, massive splenomegaly, elevated levels of inflammatory cytokines, severe constitutional symptoms, cachexia and premature death. INCB018424 is a potent, selective inhibitor of JAK 1 and 2 which has demonstrated impressive clinical activity in the early portion of a phase 1/2 study in patients with PMF and Post-PV/ET MF.</jats:p> <jats:p>Methods : Following the initial dose escalation phase with a BID schedule (N=11), both twice daily (10 mg BID to 25 mg BID, N=56) and once daily (25 mg QD to 200 mg QD, N= 37) dose regimens were explored. Endpoints included spleen size assessed by manual palpation, constitutional symptoms assessed using the Modified Myelofibrosis Symptom Assessment Form (MFSAF) and JAK2 allele burden. Exercise capacity is being assessed using the Six Minute Walk Test (6MWT), and body mass and composition are being assessed using standard methods. Safety was assessed by collection of adverse events and monitoring of laboratory data.</jats:p> <jats:p>Results : Over 100 patients are currently enrolled in the study, with a mean exposure to drug of &amp;gt; 5 months. Twenty percent of patients have received INCB018424 for &amp;gt; 9 months. INCB018424 is associated with a rapid reduction of splenomegaly in over 93% of patients from a mean baseline spleen size &amp;gt;20 cm, with 50% or greater reduction being observed in 35% of patients dosed with 10 mg BID or 50 mg QD, and 59% of patients dosed with 25mg BID regimens. These declines nearly always occur within the first month of therapy, with further, slower decreases often observed thereafter. In responding patients, spleen size reduction persists for the duration of therapy (currently up to one year follow-up). Constitutional symptoms are reported with high frequency in the study population as assessed by the MFSAF: night sweats, pruritis and fatigue were reported by &amp;gt;60%, &amp;gt;45% and &amp;gt;90% of patients respectively. Improvements in self-assessed symptom scores (mean % improvement of 40% to 60%) occurred by the first assessment at week 2. Activity limitations are also reported by a high proportion of MF patients; 70% of respondents reported impaired ability to exercise or get around, with a mean score &amp;gt;5 on the 11-point MFSAF scale; INCB018424 therapy was associated with rapid (within 2 weeks) and marked (40% or more) improvement in self-assessed score. There was a dose-dependent weight gain, most pronounced in patients with the lowest body mass index (BMI) values at baseline. Profound reductions in inflammatory cytokines were observed by the first evaluation at week 2 in virtually all patients, and were maintained during therapy. INCB018424 is generally well tolerated with the primary toxicity being dose-dependent grade 3 or 4 reversible thrombocytopenia which occurred in 0%, 18% and 32% of patients dosed with 10 mg BID, 50 mg QD or 25 mg BID.</jats:p> <jats:p>Conclusions : INCB18424 shows unprecedented and durable clinical efficacy in reducing spleen size and improving constitutional symptoms in patients with MF. Results from proactive dose modification regimens, assessments of exercise capacity, MRI-based spleen volume assessment and body composition determination will be presented.</jats:p> The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF). Blood
spellingShingle Verstovsek, Srdan, Kantarjian, Hagop M., Pardanani, Animesh D., Thomas, Deborah, Cortes, Jorge, Mesa, Ruben A., Hogan, William J., Redman, John R., Erickson-Viitanen, Sue, Levy, Richard, Vaddi, Kris, Bradley, Edward, Fridman, Jordan, Tefferi, Ayalew, Blood, The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF)., Cell Biology, Hematology, Immunology, Biochemistry
title The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
title_full The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
title_fullStr The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
title_full_unstemmed The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
title_short The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
title_sort the jak inhibitor, incb018424, demonstrates durable and marked clinical responses in primary myelofibrosis (pmf) and post-polycythemia/essential thrombocythemia myelofibrosis (post pv/etmf).
title_unstemmed The JAK Inhibitor, INCB018424, Demonstrates Durable and Marked Clinical Responses in Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post PV/ETMF).
topic Cell Biology, Hematology, Immunology, Biochemistry
url http://dx.doi.org/10.1182/blood.v112.11.1762.1762